Key result
Pharmacoinvasive strategy for STEMI is linked to higher 3-month heart failure risk versus PPCI.
Why the study?
Primary PCI is effective for STEMI when performed rapidly, but outcomes of pharmacoinvasive strategy versus primary PCI when primary PCI is unavailable in the region needed comparison.
Does a pharmacoinvasive strategy improve outcomes compared to primary PCI in patients with a first attack of acute STEMI when primary PCI is unavailable within 2 hours?
Cross-Sectional (n=300)
Yes
Does a pharmacoinvasive strategy improve outcomes compared to primary PCI in patients with a first attack of acute STEMI when primary PCI is unavailable within 2 hours?
Answers are grounded in this paper and cite their sources.
A pharmacoinvasive strategy provides an effective reperfusion alternative for early STEMI when primary PCI cannot be performed within the optimal 2-hour window, though it may be associated with a slightly increased risk of heart failure.
Background: Primary percutaneous coronary intervention (PPCI) is an effective treatment for STEMI when it can be performed rapidly. Aim and objectives: To compare the outcome of the pharmaco-invasive strategy versus primary PCI for myocardial infarction when primary PCI was unavailable in our region. Patients and methods: This prospective cross-sectional study was conducted at Al Azhar University-Assuit, and Sohag Cardiac Specialized Center, Egypt, on 300 patients with a first attack of acute STEMI in the period from June 2021 to June 2023. Results: Regarding in-hospital and 3 months’ outcomes of the studied patients, most of the patients in groups I, II, and III had no in-hospital complications, while most of the patients in group IV had heart failure. Also, most of the patients in groups I, II, and III had no 3-month complications, while most of the patients in group IV had heart failure. There was a significant difference between the 4 studied groups with regard to in-hospital outcomes and 3 months’ outcome (p=0.002, <0.001, respectively). Conclusion: Pharmacoinvasive strategy in patients who received fibrinolytic therapy (streptokinase) in a non-capable center, then transferred to a PCI-capable center for PCI after successful lytic therapy (PIs) resulted in effective reperfusion in patients with early STEMI who could not undergo primary PCI within 2 h after the first medical contact. This can provide a wide time window for PCI when the application of primary PCI within the optimal time limit is not possible. However, it was associated with a slightly increased risk of heart failure.
No takes yet. Share an insight, caveat, or question.
Abdelbaset et al. (2026) conducted a cross-sectional in acute STEMI (n=300). Pharmacoinvasive strategy vs. Primary PCI was evaluated on In-hospital and 3 months' outcomes (p=0.002, <0.001). A pharmacoinvasive strategy for early STEMI resulted in effective reperfusion but was associated with a increased risk of heart failure at 3 months compared to other groups.
Synapse has enriched 10 related papers. Consider them for comparative context: